Navigation Links
Zimmer Reports Fourth Quarter and 2007 Financial Results
Date:1/29/2008


WARSAW, Ind., Jan. 29 /PRNewswire-FirstCall/ --

Fourth Quarter Highlights

-- Net Sales of $1.07 billion represents an increase of 15% reported

(10% constant currency)

-- Worldwide Reconstructive Sales increased 15% reported

(10% constant currency)

-- Diluted EPS were $1.12 reported, an increase of 10% over the prior year

period, and $1.18 adjusted, an increase of 16% over the prior year

period

Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) today reported financial results for the fourth quarter and year ended December 31, 2007. For the fourth quarter, the Company announced net sales of $1.07 billion, an increase over the prior year period of 15% reported and 10% constant currency. Diluted earnings per share for the quarter were $1.12 reported, an increase of 10%, and were $1.18 adjusted, an increase of 16%. Full year net sales were $3.9 billion, and diluted earnings per share were $3.26 reported and $4.05 adjusted, an increase of 18% adjusted over the prior year.

"We are pleased with our overall results for the fourth quarter, especially the strength of our sales across our geographic segments," said David Dvorak, Zimmer Holdings President and CEO. "Our business units around the world responded to strong underlying growth in procedures during the quarter."

During the quarter, the Company announced FDA approval of the Zimmer(R) NexGen(R) LPS-Flex Mobile Knee, only the second mobile bearing knee system to be approved for sale in the United States. The Company says that it has begun limited release of the LPS-Flex Mobile Knee and expects general availability in the U.S. in mid-2008. In addition, the Company completed its acquisitio 625.5

Inventories, net 727.8 638.3

Other current assets 214.2 214.3

Total current assets 2,082.7 1,746.2

Property, plant and equipment, net 971.9 807.1

Goodwill 2,621.4 2,515.6

Intangible assets, net 743.8 712.6

Other assets 213.9 192.9

Total Assets $6,633.7 $5,974.4

Liabilities and Shareholders' Equity

Current liabilities $748.6 $628.2

Other long-term liabilities 328.4 323.4

Long-term debt 104.3 99.6

Minority interest 2.8 2.7

Shareholders' equity 5,449.6 4,920.5

Total Liabilities and Shareholders' Equity $6,633.7 $5,974.4

Note: Reflects the adoption of Financial Accounting Standards Board

Interpretation No. 48 as of January 1, 2007.

ZIMMER HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2007 and 2006

(in millions)

2007 2006

(unaudited)

Cash flows provided by (used in)

operating activities

Net earnings $773.2 $834.5

Depreciation and amortization 230.0 197.4

Share-based compensation 70.1 76.0

Income tax benefits from stock option

exercises 30.1 11.6

Excess income tax benefits from stock

option exercises (27.0) (8.0)

Changes in operating assets and liabilities

Income taxes 70.0 68.7

Receivables (12.5) (76.9)

Inventories (57.5) (39.2)

Accounts payable and accrued expenses 59.0 (29.9)

Other assets and liabilities (64.6) 6.5

Net cash provided by operating activities 1,070.8 1,040.7

Cash flows provided by (used in)

investing activities

Additions to instruments (138.5) (126.2)

Additions to other property, plant

and equipment (192.7) (142.1)

Proceeds from sale of property,

plant and equipment - 16.2

Acquisitions, net of acquired cash (160.3) (34.9)

Net cash used in investing activities (491.5) (287.0)

Cash flows provided by (used in)

financing activities

Proceeds from employee stock compensation

plans 163.4 41.3

Excess income tax benefits from stock

option exercises 27.0 8.0

Repurchase of common stock (576.3) (798.8)

Net proceeds on lines of credit - 18.8

Net cash used in financing activities (385.9) (730.7)

Effect of exchange rates on cash and

equivalents 4.8 9.5

Increase in cash and equivalents 198.2 32.5

Cash and equivalents, beginning of period 265.7 233.2

Cash and equivalents, end of period $463.9 $265.7

ZIMMER HOLDINGS, INC.

NET SALES BY GEOGRAPHIC SEGMENT

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 and 2006

(in millions)

Three Months Ended Dec. 31, Twelve Months Ended Dec. 31,

2007 2006 %Inc/(Dec) 2007 2006 %Inc/(Dec)

(unaudited)(unaudited) (unaudited)

Americas $594.1 $537.2 11% $2,277.0 $2,076.5 10%

Europe 329.0 267.1 23 1,081.0 931.1 16

Asia Pacific 150.4 129.3 16 539.5 487.8 11

Total $1,073.5 $933.6 15 $3,897.5 $3,495.4 12

ZIMMER HOLDINGS, INC.

NET SALES BY PRODUCT CATEGORY

FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2007 and 2006

(in millions)

Three Months Ended Dec. 31, Twelve Months Ended Dec. 31,

2007 2006 %Inc/(Dec) 2007 2006 %Inc/(Dec)

(unaudited)(unaudited) (unaudited)

Reconstructive $899.0 $779.8 15% $3,260.8 $2,906.0 12%

Trauma 55.8 50.5 10 205.8 194.7 6

Spine 55.5 46.1 20 197.0 177.4 11

OSP and other 63.2 57.2 10 233.9 217.3 8

Total $1,073.5 $933.6 15 $3,897.5 $3,495.4 12

ZIMMER HOLDINGS, INC.

RECONCILIATION OF REPORTED % GROWTH TO

CONSTANT CURRENCY % GROWTH

(unaudited)

For the Three Months Ended

December 31, 2007

Foreign Constant

Reported Exchange Currency

% Growth Impact % Growth

Geographic Segments

Americas 11 % 1 % 10 %

Europe 23 12 11

Asia Pacific 16 7 9

Total 15 5 10

Product Categories

Reconstructive

Americas 11 1 10

Europe 23 12 11

Asia Pacific 16 7 9

Total 15 5 10

Knees

Americas 10 0 10

Europe 22 12 10

Asia Pacific 22 9 13

Total 15 5 10

Hips

Americas 10 1 9

Europe 16 11 5

Asia Pacific 11 7 4

Total 12 5 7

Extremities 34 4 30

Dental 30 6 24

Trauma 10 4 6

Spine 20 2 18

OSP and other 10 3 7

ZIMMER HOLDINGS, INC.

RECONCILIATION OF REPORTED % GROWTH TO

CONSTANT CURRENCY % GROWTH

(unaudited)

For the Twelve Months Ended

December 31, 2007

Foreign Constant

Reported Exchange Currency

% Growth Impact % Growth

Geographic Segments

Americas 10 % 1 % 9 %

Europe 16 9 7

Asia Pacific 11 3 8

Total 12 3 9

Product Categories

Reconstructive

Americas 10 0 10

Europe 16 9 7

Asia Pacific 12 4 8

Total 12 3 9

Knees

Americas 10 1 9

Europe 16 9 7

Asia Pacific 18 5 13

Total 12 3 9

Hips

Americas 9 1 8

Europe 12 8 4

Asia Pacific 5 2 3

Total 9 3 6

Extremities 34 3 31

Dental 23 3 20

Trauma 6 3 3

Spine 11 1 10

OSP and other 8 2 6

ZIMMER HOLDINGS, INC.

Reconciliation of Net Earnings and Adjusted Net Earnings

For the Three Months Ended December 31, 2007 and 2006

(in millions, unaudited)

Three Months

Ended December 31,

2007 2006

Net Earnings $263.8 $244.7

Acquisition, integration and other 15.7 (3.4)

Inventory step-up 0.3 -

Taxes on acquisition, integration

and other and inventory step-up (3.7) 4.1

Adjusted Net Earnings $276.1 $245.4

ZIMMER HOLDINGS, INC.

Reconciliation of Net Earnings and Adjusted Net Earnings

For the Twelve Months Ended December 31, 2007 and 2006

(in millions, unaudited)

Twelve Months

Ended December 31,

2007 2006

Net Earnings $773.2 $834.5

Settlement 169.5 -

Acquisition, integration and other 25.2 6.1

Inventory step-up 0.5 -

Taxes on settlement, acquisition,

integration and other and inventory

step-up (6.8) 2.5

Adjusted Net Earnings $961.6 $843.1

ZIMMER HOLDINGS, INC.

Reconciliation of Diluted EPS and Adjusted Diluted EPS

For the Three Months Ended December 31, 2007 and 2006

(unaudited)

Three Months

Ended December 31,

2007 2006

Diluted EPS $1.12 $1.02

Acquisition, integration and other 0.07 (0.01)

Taxes on acquisition, integration

and other (0.01) 0.01

Adjusted Diluted EPS $1.18 $1.02

ZIMMER HOLDINGS, INC.

Reconciliation of Diluted EPS and Adjusted Diluted EPS

For the Twelve Months Ended December 31, 2007 and 2006

(unaudited)

Twelve Months

Ended December 31,

2007 2006

Diluted EPS $3.26 $3.40

Settlement 0.71 -

Acquisition, integration and other 0.11 0.03

Taxes on settlement, acquisition,

integration and other (0.03) 0.01

Adjusted Diluted EPS $4.05 $3.44

ZIMMER HOLDINGS, INC.

Reconciliation of 2008 Projected Diluted EPS

and Projected Adjusted Diluted EPS

(unaudited)

Projected Twelve Months Ended December 31, 2008:

Low High

Diluted EPS $4.12 $4.17

Acquisition, integration and other, net of tax 0.08 0.08

Adjusted Diluted EPS $4.20 $4.25

n of ORTHOsoft Inc., a leader in computer surgical navigation in orthopaedics.

In the fourth quarter, the Company purchased 1.62 million common shares for a total of $116 million under its stock repurchase program, leaving authority to make up to $621.1 million in additional purchases through December 31, 2008. For the full year 2007, the Company purchased 7.2 million shares for a total of $576.3 million.

Sales Tables

The following tables provide sales results by geographic segment and product category, as well as the percentage change compared to the prior year quarter and full year on both a reported and constant currency basis.

NET SALES - THREE MONTHS ENDED DECEMBER 31, 2007

(in millions, unaudited)

Constant

Net Reported Currency

Sales % Growth % Growth

Geographic Segments

Americas $594 11 % 10 %

Europe 329 23 11

Asia Pacific 150 16 9

Total 1,073 15 10

Product Categories

Reconstructive

Americas 481 11 10

Europe 296 23 11

Asia Pacific 122 16 9

Total 899 15 10

Knees

Americas 265 10 10

Europe 124 22 10

Asia Pacific 56 22 13

Total 445 15 10

Hips

Americas 165 10 9

Europe 138 16 5

Asia Pacific 56 11 4

Total 359 12 7

Extremities 30 34 30

Dental 65 30 24

Trauma 56 10 6

Spine 55 20 18

OSP and other 63 10 7

NET SALES - TWELVE MONTHS ENDED DECEMBER 31, 2007

(in millions, unaudited)

Constant

Net Reported Currency

Sales % Growth % Growth

Geographic Segments

Americas $2,277 10 % 9 %

Europe 1,081 16 7

Asia Pacific 540 11 8

Total 3,898 12 9

Product Categories

Reconstructive

Americas 1,854 10 10

Europe 971 16 7

Asia Pacific 436 12 8

Total 3,261 12 9

Knees

Americas 1,032 10 9

Europe 408 16 7

Asia Pacific 197 18 13

Total 1,637 12 9

Hips

Americas 630 9 8

Europe 468 12 4

Asia Pacific 201 5 3

Total 1,299 9 6

Extremities 104 34 31

Dental 221 23 20

Trauma 206 6 3

Spine 197 11 10

OSP and other 234 8 6

Net earnings for the fourth quarter were $264 million on a reported basis and $276 million on an adjusted basis, an increase of 13% adjusted over the prior year period. Net earnings for the full year 2007 were $773 million on a reported basis and $962 million on an adjusted basis, an increase of 14% adjusted over the prior year.

Guidance

Full year 2008 net sales are expected to be approximately 10 to 11% over 2007, including an approximate favorable foreign currency impact of 2%. Adjusted diluted earnings per share for the full year 2008 are expected to be $4.20 to $4.25, reflecting an increase of approximately 4 to 5% over prior year. The guidance reflects the expected costs for a number of ongoing infrastructure and operating initiatives, including upgrades to the Company's U.S. sales and distribution capabilities, such as inventory tracking and instrumentation; enhancements to information technology and quality systems; increased investments in sales force and other marketing programs in the Spine, Dental and Trauma business units; and start-up costs for an expansion of worldwide manufacturing and distribution operations.

"We believe that investing today in the infrastructure needed to serve the health care market of the future will generate attractive returns in the years to come," said Dvorak.

Conference Call

The Company will conduct its year-end 2007 investor conference call today, January 29, 2008, at 8:00 a.m. Eastern Time. The live audio webcast can be accessed via Zimmer's Investor Relations website at http://investor.zimmer.com. It will be archived for replay following the conference.

Individuals who wish to dial into the conference call may do so at (888) 815-6162. International callers should dial (706) 634-9502. A digital recording will be available two hours after the completion of the conference call from January 29, 2008 to February 12, 2008. To access the recording, US/Canada callers should dial (800) 642-1687, or for International callers, dial (706) 645-9291, and enter the Conference ID, 30298922. A copy of this press release and other financial and statistical information about the periods to be presented in the conference call will be accessible through the Zimmer website at http://investor.zimmer.com.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer is a worldwide leader in designing, developing, manufacturing and marketing orthopaedic reconstructive, spinal and trauma devices, dental implants, and related orthopaedic surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer's 2007 sales were approximately $3.9 billion. The Company is supported by the efforts of more than 7,500 employees worldwide.

For more information about Zimmer, visit http://www.zimmer.com

Note on Non-GAAP Financial Measures

As used in this press release, the term "adjusted" refers to operating performance measures that exclude expenses incurred in connection with the third quarter 2007 settlement with the U.S. Department of Justice and acquisition, integration and other expenses. The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, our ability to successfully integrate acquired businesses, our compliance with the Deferred Prosecution Agreement through March 2009 and the Corporate Integrity Agreement through 2012, the impact of our enhanced healthcare compliance global initiatives and business practices on our relationships with customers and consultants, our market share and our overall financial performance, the outcome of the Department of Justice Antitrust Division investigation announced in June 2006, the outcome of the informal investigation by the U.S. Securities and Exchange Commission into Foreign Corrupt Practices Act matters announced in October 2007, price and product competition, rapid technological development, demographic changes, dependence on new product development, the mix of our products and services, supply and prices of raw materials and products, customer demand for our products and services, control of costs and expenses, our ability to form and implement alliances, international growth, governmental laws and regulations affecting our U.S. and international businesses, including tax obligations and risks, product liability and intellectual property litigation losses, reimbursement levels from third-party payors, general industry and market conditions and growth rates and general domestic and international economic conditions including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document.

ZIMMER HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE THREE MONTHS ENDED DECEMBER 31, 2007 and 2006

(in millions, except per share amounts, unaudited)

2007 2006 % Inc/(Dec)

Net Sales $1,073.5 $933.6 15 %

Cost of products sold 253.9 207.5 22

Gross Profit 819.6 726.1 13

Research and development 50.8 45.6 11

Selling, general and administrative 401.2 345.6 16

Acquisition, integration and other

expense 15.7 (3.4) 576

Operating expenses 467.7 387.8 21

Operating Profit 351.9 338.3 4

Interest income, net 1.1 1.5 (31)

Earnings before income taxes and

minority interest 353.0 339.8 4

Provision for income taxes 89.0 95.0 (6)

Minority interest (0.2) (0.1) (104)

Net Earnings $263.8 $244.7 8

Earnings Per Common Share

Basic $1.13 $1.03 10

Diluted $1.12 $1.02 10

Weighted Average Common Shares

Outstanding

Basic 233.3 238.5

Diluted 234.8 241.0

ZIMMER HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF EARNINGS

FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2007 and 2006

(in millions, except per share amounts)

2007 2006 % Inc/(Dec)

(unaudited)

Net Sales $3,897.5 $3,495.4 12 %

Cost of products sold 875.9 780.1 12

Gross Profit 3,021.6 2,715.3 11

Research and development 209.6 188.3 11

Selling, general and administrative 1,489.7 1,355.7 10

Settlement 169.5 - 100

Acquisition, integration and other

expense 25.2 6.1 312

Operating expenses 1,894.0 1,550.1 22

Operating Profit 1,127.6 1,165.2 (3)

Interest income, net 4.0 3.8 5

Earnings before income taxes and

minority interest 1,131.6 1,169.0 (3)

Provision for income taxes 357.9 334.0 7

Minority interest (0.5) (0.5) (17)

Net Earnings $773.2 $834.5 (7)

Earnings Per Common Share

Basic $3.28 $3.43 (4)

Diluted $3.26 $3.40 (4)

Weighted Average Common Shares

Outstanding

Basic 235.5 243.0

Diluted 237.5 245.4

ZIMMER HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)

December 31, December 31,

2007 2006

(unaudited)

Assets

Current Assets:

Cash and equivalents $463.9 $265.7

Restricted cash 2.5 2.4

Receivables, net 674.3
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System
2. Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results
3. Zimmer Holdings to Present at JPMorgan Healthcare Conference
4. Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee
5. Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman
6. Zimmer Holdings to Present at Upcoming Investor Conferences
7. Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid
8. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results
9. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
10. Amylin Pharmaceuticals Reports 2007 Financial Results
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... It’s that time of year when most people have forgotten ... Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest School athletic ... , That’s why one of her first decisions when her IAAM two-year presidency began ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... and production of its newest mobility device, the StandUp Walker. Made entirely in ... design in the last 50 years. , StandUp Walker’s novel patent-pending design offers ...
(Date:2/9/2016)... New York, NY (PRWEB) , ... February 09, 2016 , ... ... announce the appointment of Dr. David Hung to the company´s Board of Directors. ... is a world class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... to expand access to affordable hearing aids , increase industry transparency, and ... in the United States. , “For the average consumer, the hearing aid industry ...
(Date:2/9/2016)... ... 09, 2016 , ... Sir Grout, the leading hard surface ... announce that many of their franchises have received the Super Service Award from ... franchises received customer recognition through positive reviews and testimonials, as well as evaluations ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... 9, 2016  Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... fiscal 2016 first quarter ended December 31, 2015. ... 2016 First Quarter Highlights , Revenue of $36.5 ... of 2015 , Domestic Radiation Measurement services revenues increased ...
(Date:2/9/2016)... , Feb. 9, 2016  Jazz Pharmaceuticals plc ... report its 2015 fourth quarter and full year financial ... of the financial markets.  Company management will host a ... p.m. EST/9:30 p.m. GMT to discuss fourth quarter and ... and financial update and guidance for 2016 financial results. ...
(Date:2/9/2016)... Amarantus BioScience Holdings, Inc. ... for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... Source Capital Group,s 2016 Disruptive Growth & Healthcare Conference ... New York City . The Company,s presentation ... 12:30 pm by Gerald E. Commissiong , President ...
Breaking Medicine Technology: